Leerink Partnrs Has Optimistic Outlook of LENZ Q3 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for LENZ Therapeutics in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($0.80) per share for the quarter, up from their previous forecast of ($0.87). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($0.45) EPS.

Several other research analysts have also recently weighed in on the stock. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a research report on Monday, April 14th. They issued an “overweight” rating and a $51.00 price objective on the stock. TD Cowen initiated coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, May 8th. Finally, Citigroup upped their price objective on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $46.60.

LENZ Therapeutics Trading Down 1.4%

LENZ stock opened at $28.96 on Monday. The company’s 50 day moving average is $24.82 and its 200 day moving average is $27.33. The stock has a market cap of $815.11 million, a price-to-earnings ratio of -16.36 and a beta of 0.41. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LENZ. Barclays PLC grew its position in LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company’s stock valued at $391,000 after acquiring an additional 12,051 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in LENZ Therapeutics during the fourth quarter valued at approximately $1,270,000. SG Americas Securities LLC grew its position in LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after acquiring an additional 935 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in LENZ Therapeutics during the fourth quarter valued at approximately $168,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in LENZ Therapeutics during the fourth quarter valued at approximately $29,000. 54.32% of the stock is currently owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.